Call For Artists to Submit Work for Frames of Mind Campaign by Allergan

In an effort to encourage people with migraine to share their experiences through art, Allergan announces its Frames of Mind campaign. This interactive project invites artists to share their work to visually represent the impact that migraine can have on patients’ everyday lives.

Artists can submit digital, high resolution versions of the original works of art via email to [email protected], noting the artist’s name, location, and contact information. Deadline for submission is May 26, 2017.

Select “migraine masterpieces” will be presented in a special exhibit at migraine-focused events and meetings, along with educational information about migraine symptoms, triggers and coping techniques.

To read the full press release, click here.

Posted in

Sweet Pea’s Battle with Pediatric Cancer

October 5, 2017

October is Breast Cancer Awareness Month. Football and baseball players will be wearing pink. Fundraising walks will raise millions of dollars. It’s a worthy cause. I’m happy to say that I’ve had a friend beat it twice. However, did you know that September was National Childhood Cancer Awareness Month? This year I decided I was…

Photo Fridays- Migraine.com Connexion Conference

March 24, 2017

On Tuesday and Wednesday of this week, Health Union (parent company of Migraine.com) invited all the HQ staff, writers and moderators to join together for the first time at their new space in Philly. One of our co-founders said it best- “Welcome Home.” And that’s exactly what these 2 days felt like.

Questions on CGRP

Real News on CGRP Access

May 22, 2018

Aimovig, the first CGRP inhibitor drug, was approved by the FDA on May 17, 2018. This is extremely exciting news, but there are a lot of questions swirling around as many of us are anxious to try this new medicine. For the most up-to-date information about Aimovig visit Aimovig.com. The site includes Frequently Asked Questions, information…

Leave a Comment

You must be logged in to post a comment.